Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

Sonal Singh; Yoon K. Loke; Spangler, John G.; Furberg, Curt D.
September 2011
CMAJ: Canadian Medical Association Journal;9/6/2011, Vol. 183 Issue 12, p1359
Academic Journal
Background: There have been postmarketing reports of adverse cardiovascular events associated with the use of varenicline, a widely used smoking cessation drug. We conducted a systematic review and meta-analysis of randomized controlled trials to ascertain the serious adverse cardiovascular effects of varenicline compared with placebo among tobacco users. Methods: We searched MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, websites of regulatory authorities and registries of clinical trials, with no date or language restrictions, through September 2010 (updated March 2011) for published and unpublished studies. We selected double-blind randomized controlled trials of at least one week's duration involving smokers or people who used smokeless tobacco that reported on cardiovascular events (ischemia, arrhythmia, congestive heart failure, sudden death or cardiovascular-related death) as serious adverse events associated with the use of varenicline. Results: We analyzed data from 14 double-blind randomized controlled trials involving 8216 participants. The trials ranged in duration from 7 to 52 weeks. Varenicline was associated with a significantly increased risk of serious adverse cardiovascular events compared with placebo (1.06% [52/4908] in varenicline group v. 0.82% [27/3308] in placebo group; Peto odds ratio [OR] 1.72, 95% confidence interval [CI] 1.09-2.71; I2 = 0%). The results of various sensitivity analyses were consistent with those of the main analysis, and a funnel plot showed no publication bias. There were too few deaths to allow meaningful comparisons of mortality. Interpretation: Our meta-analysis raises safety concerns about the potential for an increased risk of serious adverse cardiovascular events associated with the use of varenicline among tobacco users.


Related Articles

  • Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Yu-Hao Zhou; Xiu-Qiang Ma; Cheng Wu; Jian Lu; Shan-Shan Zhang; Jia Guo; Shun-Quan Wu; Xiao-Fei Ye; Jin-Fang Xu; Jia He // PLoS ONE;Jun2012, Vol. 7 Issue 6, p1 

    Background: Anti-obesity drugs are widely used to prevent the complications of obesity, however, the effects of antiobesity drugs on cardiovascular risk factors are unclear at the present time. We carried out a comprehensively systematic review and meta-analysis to assess the effects of...

  • Smokeless tobacco and cardiovascular risk in non-Caucasian patients. Tully, R. P.; Zaheer, M.; Saha, B. // BJA: The British Journal of Anaesthesia;Jul2011, Vol. 107 Issue 1, p105 

    No abstract available.

  • Second-Generation Antipsychotic Agents: A Review of Safety Profiles. Yurkov, Vladimir; Jha, Sarita; Collins, David M.; Alessi-Severini, Silvia // Current Psychiatry Reviews;Feb2012, Vol. 8 Issue 1, p49 

    Early clinical trials had suggested a better safety profile for the second-generation antipsychotics (SGAs; e.g. risperidone, olanzapine, quetiapine, aripiprazole) compared to the older first-generation agents (FGAs; e.g. haloperidol and phenothiazines); however, new long-term studies have...

  • Rosiglitazone and the Risk of Adverse Cardiovascular Outcomes. Winterstein, A. G. // Clinical Pharmacology & Therapeutics;Jun2011, Vol. 89 Issue 6, p776 

    In this article the author discusses two, key studies reviewed by an advisory board of the U.S. Food and Drug Administration (FDA) on rosiglitazone and its cardiovascular risks. He says that both studies put the Medicare evaluation to be less problematic than the randomized clinical trial. He...

  • Triple-Combination Pharmacotherapy for Medically III Smokers. Steinberg, Michael B.; Greenhaus, Shelley; Schmelzer, Amy C.; Bover, Michelle T.; Foulds, Jonathan; Hoover, Donald R.; Carson, Jeffrey L. // Annals of Internal Medicine;4/7/2009, Vol. 150 Issue 7, p447 

    Background: Smokers with medical illnesses are at particular risk for complications caused by tobacco. Clinical trial data on the effectiveness of triple-combination pharmacotherapy for tobacco dependence treatment in these high-risk smokers are not available. Objective: To evaluate extended...

  • New evidence of CV risk with testosterone therapy.  // Reactions Weekly;1/18/2014, Issue 1484, p3 

    The article reports on a research finding which indicate that men who received testosterone therapy had an increased risk of mortality and cardiovascular adverse events.

  • Anagrelide use linked to cardiovascular risk.  // Reactions Weekly;02/16/2013, Issue 1439, p4 

    The article reports on the addition of a warning to the labelling of Xagrid due to the risk cardiovascular adverse events in patients with essential thrombocytopaenia.

  • Antihypertensive drugs may increase cholesterol patients' CVD risk.  // Geriatrics;Nov99, Vol. 54 Issue 11, p71 

    Presents an abstract on the study, `Effect of hypertension and its treatment on lipid, lipoprotein (a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia,' by J.A. Papadakis, E.S. Ganotakis, et al, from the July 1999 issue of the American Journal of Hypertension.

  • New Challenges Ahead for the Newer Oral Thrombin Inhibitors that Aim at Replacing Warfarin in Clinical Practice-Any Role for Scientific Societies in the Debate? Kaski, Juan-Carlos // Cardiovascular Drugs & Therapy;Aug2012, Vol. 26 Issue 4, p359 

    The author comments on a meta-analysis of trials which highlighted the association between thrombin inhibitors and increased risk of myocardial infarction (MI). According to the author, these findings have implication for both clinicians and the individual patient in a clinical setting. He...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics